ImmuneBridge
LLM & Generative AI · Artificial Intelligence
$27.8Mtotal raised · 3 rounds on record
$5.6Mlatest round · Venture round · Mar 2025 · 19 mo ago
4backers · NFX, Healthspan Capital
7team · US Form 5500 (plan participants) · Dec 2025 · -13% in a year
Overview
Building the next generation of cell therapies. Cell therapies face key challenges that limit their efficacy and accessibility:.
Funding and backers
Total raised
$27.8M
3 rounds on record
Latest round
$5.6M
Venture round · Mar 2025 · 19 mo ago
Team
7
US Form 5500 (plan participants) · Dec 2025 · -13% in a year
Backers
4
NFX, Healthspan Capital
The money's age
Due for its next round
19 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 24, 2025
Raised a round Venture round $5.6M · SEC Form D
Apr 11, 2023
Raised a round Seed $12M
Dec 27, 2022
Raised a round Venture round $10.2M · SEC Form D
2022
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Mar 2025 | $5.6M | — | SEC Form D |
| Seed | Apr 2023 | $12M | — | businesswire.com |
| Venture round | Dec 2022 | $10.2M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | ImmuneBridge Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Peretz PartenskyExecutive Officer, DirectorSEC Form D
Stuart JacobsonExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
At Globeholder AI we are creating the next generation of intelligence — sovereign, grounded, and world-aware. Meet our team and mission.
Waypoint Bio is a biotechnology company pioneering the next generation of cell therapies for solid tumors.
NinjaTech AI is a business developing the first genuine next-generation personal assistant using generative AI.
LENZO develops adaptable AI computing platforms built on TokenProcessor™ technology, enabling robotics, autonomous systems, advanced…
The largest consumer AI ad platform. Kontext leverages LLMs to deliver unique ad formats tailored to the next generation of consumer apps…
Designer cell therapies for pets first and their people next.
People
Peretz Partensky
Executive Officer, Director
Stuart Jacobson
Executive Officer, Director
Alicia Jackson
Director
Cheryl Zimberlin
Director
Gregory Bonfiglio
Director
Dylan Morris
Director
Mary Warren
Director
Nadiya Ishnazarova
Director
Omri Amirav-Drory
Director
Thomas Farrell
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Healthspan CapitalVia a fund
M VenturesVia a fund
NFXVia a fund
Insight PartnersVia a fund
812 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
ImmuneBridge Secures $7.7M to Open Cell Therapy Manufacturing Platform to Biotech Partners
ImmuneBridge secures $7.7M to open its breakthrough cell therapy manufacturing platform to biotech partners, enabling the production of...
Read more
Report
ImmuneBridge entscheidet sich für Sapio Sciences Electronic Lab Notebook für die Modernisierung und Skalierung des Unternehmensdatenmanagements
Alle IT-Nachrichten auf Silicon.de
Read more
Report
ImmuneBridge entscheidet sich für Sapio Sciences Electronic Lab Notebook für die Modernisierung und Skalierung des Unternehmensdatenmanagements
Das reaktionsschnelle, kompetente Kundenbetreuungsteam von Sapio hat die Plattform in kürzester Zeit konfiguriert, um die einzigartige Forschung von ImmuneBridge zu optimieren und zu beschleunigen ImmuneBridge
Read more
Report
ImmuneBridge Chooses Sapio Sciences Electronic Lab Notebook to Modernize and Scale Enterprise Data Management
Sapio's responsive, expert customer support team rapidly configured the platform to optimize and accelerate ImmuneBridge's unique research ImmuneBridge, a developer of allogeneic, off-the-shelf cellular
Read more
Report
ImmuneBridge Chooses Sapio Sciences Electronic Lab Notebook to Modernize and Scale Enterprise Data Management
Read more
Report
Allogeneic Cellular Medicine Company ImmuneBridge Raises $12 Million
ImmuneBridge - a biotechnology company using nature's innate intelligence to fight cancer - announced the closing of an oversubscribed $12 million seed financing.
Read more
Report
ImmuneBridge Raises $12M from M Ventures and Insight Partners to Advance Novel Natural Killer (NK) Cell-based Immunotherapies
Read more
Report
Long-awaited findings from the IMMUNEBRIDGE study reveal gaps in SARS-CoV-2 immunity
Moderate to high protection was observed against severe COVID-19 in most age groups, while low protection was observed against infection for all ages.
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
San Francisco
United States
HQ
Contact Us
50-200 est. staff
2122 Bryant St, San Francisco, CA 94110